Pure CBD and THC Formulations Showed Moderate Benefits for Anxiety and PTSD in Meta-Analysis of 21 Trials

Across 21 placebo-controlled RCTs covering social anxiety, GAD, PTSD, OCD, and Tourette syndrome, pure CBD compounds showed a moderate significant effect (SMD -0.61, 95% CI -1.15 to -0.07). THC-dominant compounds also showed moderate significance (SMD -0.65, 95% CI -1.06 to -0.24). However, CBD-THC mixtures did not reach significance (SMD -0.73, 95% CI -2.00 to 0.55). Pharmaceutical-grade formulations appeared to outperform non-standardized extracts.

Systematic review and meta-analysis searching PubMed, Embase, PsycInfo, Web of Science, Scielo, and Lilacs for placebo-controlled RCTs. 21 trials included: 5 for social anxiety, 1 GAD, 7 PTSD, 1 OCD, 7 Tourette syndrome. Separate meta-analyses by cannabinoid subtype. Standardized mean differences calculated using Jamovi software.

This is one of the most comprehensive meta-analyses to date separating cannabinoid types across anxiety-related conditions. The finding that pharmaceutical-grade formulations outperform non-standardized extracts has direct implications for both clinical practice and regulation of medical cannabis for mental health conditions.

The superiority of pure formulations over mixtures challenges the popular "entourage effect" hypothesis for mental health conditions. It suggests that for anxiety and PTSD, precise dosing of specific cannabinoids may matter more than whole-plant approaches, aligning with pharmaceutical rather than dispensary models of care.

Small sample sizes across most included trials. Heterogeneous study designs, doses, and outcome measures. Some conditions had very few trials (1 each for GAD and OCD). Cannot compare conditions head-to-head. THC results driven partly by Tourette syndrome trials which may involve different mechanisms than anxiety.